Zacks de estoque drrx

Compre calçados e moda online na Dafiti. Aqui você encontra as melhores marcas de sapatos, roupas, bolsas, acessórios, perfumes, produtos de beleza e decoração. Aproveite! Zacks Investment Research Page 3 scr.zacks.com 150mg severe cohort (n=4) is now enrolling. This is the final group of severe patients, following completion of which is expected to be followed by DRRX meeting with FDA to discuss details related to a pathway for U.S. regulatory approval o Moderate cohort January 10, 2020 MBII: Marrone Bio Innovations adds to credit facility based on short term assets. Our estimates do not include any financials from the recent acquisitions.

DRRX: DURECT Corporation Detailed Estimate. Get the latest Detailed Estimate from Zacks Investment Research. DRRX: DURECT Corporation price and EPS surprise. Get the latest price and EPS surprise information from Zacks Investment Research. DRRX: DURECT Corporation equity research. Get the latest equity research information from Zacks Investment Research. DRRX: DURECT Corporation - Full Company Report. Get the latest Full Company Report for DURECT Corporation from Zacks Investment Research Should I buy Durect Corporation (DRRX)? Use the Zacks Rank and Style Scores to find out is DRRX is right for your portfolio. DRRX: DURECT Corporation - Earnings Announcements. Stay up to date with lastest Earnings Announcements for DURECT Corporation from Zacks Investment Research

DRRX: DURECT Corporation broker recommendation chart. Get the latest chart with broker recommendations from Zacks Investment Research.

By Grant Zeng, CFA NASDAQ:DRRX The Development and Commercialization Deal On May 8, 2017, Durect (NASDAQ:DRRX) announced a development and commercialization agreement with Sandoz AG, a division of Novartis (NVS), to develop and market in the United States Durect’s POSIMIR® (SABER®-Bupivacaine), an investigational locally-acting, non-opioid Os retornos mensais são então compostos para chegar ao retorno anual. Apenas os estoques de Zacks Rank incluídos nas carteiras hipotéticas de Zacks no início de cada mês estão incluídos nos cálculos de devolução. Os estoques de Zack Ranks podem, e muitas vezes, mudar ao longo do mês. Zacks Small-Cap Research Sponsored Impartial - Comprehensive scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 June 27, 2019 Brian Marckx, CFA bmarckx@zacks.com Ph (312) 265-9474 Favorable FDA Decision on POSIMIR Would Likely Mean Significant Upside to Our Model We value DRRX using sum-of-the-parts, with most of the value Os retornos mensais são então compostos para chegar ao retorno anual. Apenas os estoques de Zacks Rank incluídos nas carteiras hipotéticas de Zacks no início de cada mês estão incluídos nos cálculos de devolução. Os estoques de Zack Ranks podem, e muitas vezes, mudar ao longo do mês. Compre calçados e moda online na Dafiti. Aqui você encontra as melhores marcas de sapatos, roupas, bolsas, acessórios, perfumes, produtos de beleza e decoração. Aproveite!

Q1 Financial Results and Operational Update Last week Durect Corp (DRRX) reported financial results for their first quarter ending March 31st and provided a pipeline development update. The development update was extensive and included highly compelling results of the first 10 patients enrolled in the DUR-928 Phase 2a alcoholic hepatitis trial.

DRRX: DURECT Corporation Detailed Estimate. Get the latest Detailed Estimate from Zacks Investment Research.

DRRX: Gilead Agreement, Near-Term Value-Inflection Opportunities Make DRRX Particularly Attractive at Current Valuation Zacks Small Cap Research Aug-01-19 04:05PM DURECT Corporation Announces Second Quarter 2019 Financial Results and Update of Programs PR Newswire

scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 May 16, 2019 Brian Marckx, CFA bmarckx@zacks.com Ph (312) 265-9474 Highly Compelling Initial Ph2a DUR-928 Alcoholic Hepatitis Data. Final Data Later This Year Could Be Value Inflection Event We value DRRX using sum-of-the-parts, with most of the value 27/12/2019 · DURECT Corporation Common Stock (DRRX) Earnings Report Date. Earnings announcement* for DRRX: Data is currently not available. Our vendor, Zacks Investment Research, hasn't provided us with the upcoming earnings report date. Earnings Per Share Estimated Reported. Sign up to SCR Digest, our FREE weekly newsletter, and receive our Notes emailed directly to you. bmarckx@zacks.com Ph (312) 265-9474 DRRX: Pipeline Update: Focus Is On Accelerating DUR-928 in NASH and Other High-Potential Indications We value DRRX using sum-of-the-parts, with most of the value related to DUR-928 based on pricing of recent NASH-targeted M&A transactions as a proxy. By Brian Marckx, CFA. NASDAQ:DRRX | NASDAQ:PCRX. READ THE FULL DRRX RESEARCH REPORT. POSIMIR CRL Response Made. Favorable Decision Would Likely Mean Significant Upside to Our Model This morning, Durect (NASDAQ:DRRX) announced that they submitted a full response to FDA’s Complete Response Letter for POSIMIR, which Durect received in February 2014.

Find the latest news headlines from DURECT Corporation Common Stock (DRRX) at Nasdaq.com.

jnapodano@zacks.com DRRX: Remoxy Update Expect This Fall, Meanwhile The Pipeline Rolls Forward. Zacks Investment Research Page 2 scr.zacks.com WHATS NEW Recent Financial Results On August 5, 2013, Durect Corp. reported financial results for the second … 4) Do you have data/values for the risk level, type of stock, industry and Zacks rank in industry on your cover page? 5) Do your quarterly EPS estimates sum to your annual? If … DRRX: Pipeline Update: Focus Is On Accelerating DUR-928 in NASH and Other High-Potential Indications. January 11, 2019 10:45 am Zacks Small Cap Research 0. Research articles, as seen here, are part of the service Zacks provides and Zacks receives quarterly payments totaling a maximum fee of $30,000 annually for these services. NASDAQ:DRRX The Patent Deal On October 2, 2017, DURECT Corporation (DRRX) announced a patent purchase agreement with Indivior UK Limited, an affiliate of Indivior PLC (INDV.L). Pursuant to the agreement, DURECT has assigned certain of its U.S. patent rights to Indivior. Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm engaged by the issuer for providing non-investment banking services to this issuer and expects to receive additional compensation for such non-investment banking services provided to this issuer. DURECT Co. (NASDAQ:DRRX) has earned an average broker rating score of 1.67 (Buy) from the three analysts that provide coverage for the company, Zacks Investment Research reports. One research analyst has rated the stock with a hold rating and two have assigned a strong buy rating to the company. Brokerages have set a 1-year consensus […] DRRX: Gilead Agreement, Near-Term Value-Inflection Opportunities Make DRRX Particularly Attractive at Current Valuation Zacks Small Cap Research Aug-01-19 04:05PM DURECT Corporation Announces Second Quarter 2019 Financial Results and Update of Programs PR Newswire

Zacks Small-Cap Research Sponsored Impartial - Comprehensive scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 June 27, 2019 Brian Marckx, CFA bmarckx@zacks.com Ph (312) 265-9474 Favorable FDA Decision on POSIMIR Would Likely Mean Significant Upside to Our Model We value DRRX using sum-of-the-parts, with most of the value Os retornos mensais são então compostos para chegar ao retorno anual. Apenas os estoques de Zacks Rank incluídos nas carteiras hipotéticas de Zacks no início de cada mês estão incluídos nos cálculos de devolução. Os estoques de Zack Ranks podem, e muitas vezes, mudar ao longo do mês.